Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Aug 15;102(4):401-3.
doi: 10.1016/j.amjcard.2008.03.073. Epub 2008 May 28.
Affiliations
- PMID: 18678295
- DOI: 10.1016/j.amjcard.2008.03.073
Randomized Controlled Trial
Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents
Mohammed Abuzahra et al. Am J Cardiol. 2008.
Abstract
Adequate antiplatelet therapy is paramount for good clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). The purpose of this study was to determine whether a high-dose regimen of clopidogrel in patients undergoing PCI is superior to standard dosing. A total of 119 patients undergoing PCI were blindly randomized in 2:1 fashion to receive clopidogrel loading 600 mg on the table immediately before PCI and 75 mg 2 times/day for 1 month (high-dose group) versus standard dosing (300 mg loading and 75 mg/day; low-dose group). Platelet aggregation was measured using light transmission aggregometry at baseline, 4 hours, and 30 days. The composite of cardiovascular death, myocardial infarction, and target vessel revascularization was studied at 30 days in addition to major and minor bleeding. Baseline characteristics and baseline platelet aggregation were similar in the 2 groups. Percent inhibitions of platelet activity were 41% and 27% in the high-dose group versus 19% and 10% in the low-dose group at 4 hours and 30 days (p = 0.046 and 0.047, respectively). Composite clinical end points were 10.3% in the high-dose group and 23.8% in the low-dose group (p = 0.04). No difference was noted in major or minor bleeding. In conclusion, a higher loading and maintenance dose of clopidogrel in patients undergoing PCI results in superior platelet inhibition and decreased cardiovascular events without increasing bleeding complications.
Similar articles
- A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
Han YL, Wang B, Li Y, Xu K, Wang SL, Jing QM, Wang ZL, Wang DM, Ma YY, Wang G. Han YL, et al. Chin Med J (Engl). 2009 Apr 5;122(7):793-7. Chin Med J (Engl). 2009. PMID: 19493391 Clinical Trial. - Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA. Angiolillo DJ, et al. Thromb Haemost. 2008 Jan;99(1):161-8. doi: 10.1160/TH07-09-0562. Thromb Haemost. 2008. PMID: 18217149 Clinical Trial. - Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z, Kala P. Motovska Z, et al. Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Clin Ther. 2008. PMID: 19281914 Review. - Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
Lemesle G, Delhaye C, Sudre A, Broucqsault D, Rosey G, Bauters C, Lablanche JM. Lemesle G, et al. Am Heart J. 2009 Feb;157(2):375-82. doi: 10.1016/j.ahj.2008.09.013. Epub 2008 Nov 1. Am Heart J. 2009. PMID: 19185648 - Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S, Roe MT. Steinhubl S, et al. Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. doi: 10.1111/j.1527-3466.2007.00013.x. Cardiovasc Drug Rev. 2007. PMID: 17614940 Review.
Cited by
- Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease.
Gurbel PA, Tantry US. Gurbel PA, et al. Curr Treat Options Cardiovasc Med. 2009 Feb;11(1):22-32. doi: 10.1007/s11936-009-0003-y. Curr Treat Options Cardiovasc Med. 2009. PMID: 19141258 - Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.
Gresham C, Levine M, Ruha AM. Gresham C, et al. J Med Toxicol. 2009 Dec;5(4):242-9. doi: 10.1007/BF03178275. J Med Toxicol. 2009. PMID: 19876861 Free PMC article. - Clinical importance of aspirin and clopidogrel resistance.
Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Papp E, Szapary L, Kesmarky G, Toth K. Feher G, et al. World J Cardiol. 2010 Jul 26;2(7):171-86. doi: 10.4330/wjc.v2.i7.171. World J Cardiol. 2010. PMID: 21160749 Free PMC article. - Antiplatelet agents in hemodialysis.
Migliori M, Cantaluppi V, Scatena A, Panichi V. Migliori M, et al. J Nephrol. 2017 Jun;30(3):373-383. doi: 10.1007/s40620-016-0367-5. Epub 2016 Dec 8. J Nephrol. 2017. PMID: 27928736 Review. - Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy.
Reid C, Alturki A, Yan A, So D, Ko D, Tanguay JF, Bessissow A, Mehta S, Goodman S, Huynh T. Reid C, et al. CJC Open. 2020 Feb 24;2(3):118-128. doi: 10.1016/j.cjco.2020.02.005. eCollection 2020 May. CJC Open. 2020. PMID: 32462125 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous